Literature DB >> 19758188

NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis.

Smriti K Raychaudhuri1, Siba P Raychaudhuri.   

Abstract

A contributing role of nerve growth factor (NGF)-mediated neuroimmunologic mechanisms has provided a new dimension in the understanding of various cutaneous and systemic inflammatory diseases. Recent evidence implicates NGF as a key mediator of inflammation and pain. NGF influences an inflammatory reaction by regulating neuropeptides, angiogenesis, cell trafficking molecules, and T cell activation. All of these functions of NGF are relevant in maintenance or initiation of the critical biologic events in various rheumatologic conditions. The recognition of a pathologic role of NGF and its receptor system has provided an attractive opportunity to develop a novel class of therapeutics for inflammatory diseases and chronic pain syndromes. In this chapter we will discuss the role of NGF and its receptor system in psoriatic disease, inflammatory arthritis, and arthritic pain of osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758188     DOI: 10.1111/j.1749-6632.2009.04652.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Pain-induced skin autoimmunity.

Authors:  Francesca Odoardi; Winfried Neuhuber; Alexander Flügel
Journal:  Cell Res       Date:  2014-06-20       Impact factor: 25.617

Review 2.  Psychoneuroimmunology: the example of psoriasis.

Authors:  J Moynihan; E Rieder; F Tausk
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

3.  [Stress and the molecular basis of psychosomatics].

Authors:  E M J Peters
Journal:  Hautarzt       Date:  2013-06       Impact factor: 0.751

4.  NGF - the TrkA to successful pain treatment.

Authors:  Vinayak Kumar; Brandon A Mahal
Journal:  J Pain Res       Date:  2012-08-17       Impact factor: 3.133

5.  Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.

Authors:  Ramesh Narayanan; Muralimohan Yepuru; Christopher C Coss; Zhongzhi Wu; Matthew N Bauler; Christina M Barrett; Michael L Mohler; Yun Wang; Juhyun Kim; Linda M Snyder; Yali He; Nelson Levy; Duane D Miller; James T Dalton
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 6.  Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders.

Authors:  Michael P Schön
Journal:  Front Immunol       Date:  2019-07-26       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.